---
title: "CRVO.US (CRVO.US) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/CRVO.US/news.md"
symbol: "CRVO.US"
name: "CRVO.US"
parent: "https://longbridge.com/zh-CN/quote/CRVO.US.md"
datetime: "2026-03-17T16:27:02.455Z"
locales:
  - [en](https://longbridge.com/en/quote/CRVO.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CRVO.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CRVO.US/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/CRVO.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/CRVO.US/news.md)


# CRVO.US (CRVO.US) — 相关新闻

### [CervoMed Flat on Q4, FY Results](https://longbridge.com/zh-CN/news/279445718.md)
*2026-03-17T13:52:17.000Z*
> CervoMed Inc. (NASDAQ: CRVO) reported its Q4 and FY results for 2025, revealing $20.9 million in cash and equivalents, d

### [CervoMed Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate Updates](https://longbridge.com/zh-CN/news/279428295.md)
*2026-03-17T12:07:21.000Z*
### [Manufacturing and Formulation Changes Threaten Cervomed’s Neflamapimod Development Timeline and Costs](https://longbridge.com/zh-CN/news/279143559.md)
*2026-03-15T06:01:59.000Z*
> Cervomed Inc. (CRVO) has identified risks related to manufacturing changes that could increase development costs and del

### [Cervomed Announces Selection Of Formulation And Dosing Regimen For Planned Phase 3 Trial In Patients With Dementia With Lewy Bodies](https://longbridge.com/zh-CN/news/277779258.md)
*2026-03-04T12:33:24.000Z*
### [03:30 ETCervoz se zúčastní veletrhu Embedded World 2026: posílení řešení Edge AI](https://longbridge.com/zh-CN/news/277586702.md)
*2026-03-03T08:30:37.000Z*
> Cervoz Technology will participate in the Embedded World 2026 exhibition from March 10-12 in Nuremberg, Germany. The com

### [](https://longbridge.com/zh-CN/news/276266702.md)
*2026-02-18T19:43:43.000Z*
> CervoMed shares are trading higher. The company announced that neflamapimod has been selected for inclusion in the EXPER

### [CervoMed (NASDAQ:CRVO) Will Have To Spend Its Cash Wisely](https://longbridge.com/zh-CN/news/276215634.md)
*2026-02-18T10:16:00.000Z*
> CervoMed (NASDAQ:CRVO) has seen its stock rise 104% over the past year, but concerns arise as the company faces signific

### [Venus Medtech Clarifies Position on U.S. Patent Lawsuit and Market Disclosure Obligations](https://longbridge.com/zh-CN/news/273030295.md)
*2026-01-20T04:39:16.000Z*
> Venus Medtech (Hangzhou), Inc. has clarified its position regarding a U.S. patent infringement lawsuit filed by its subs